Opioid Prescribing Guidelines From US FDA Could Be A While After NASEM Report
National Academies report identifies gaps in the existing data – including on the question of whether developing prescribing guidelines would even have an impact on the opioid epidemic.
You may also be interested in...
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.
Other expedited pathways like fast track, priority review or breakthrough could be appropriate, according to new draft guidance.
Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.